Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1777985 | 0.97 | ALOX5 (0.60) | ALOX5LMNAHPGDMAPTNPC1 | |
| SCHEMBL28152490 | 0.93 | ALOX5 (0.67) | ALOX5LMNAHPGDMAPTNPC1 | |
| SCHEMBL9574659 | 0.91 | MRGPRX4 (0.64) | LMNAMAPTNPC1MAOBMRGPRX4 | |
| SCHEMBL10615958 | 0.90 | NPC1 (0.58) | MAPTNPC1MRGPRX4NR4A1NR4A2 | |
| SCHEMBL9268448 | 0.89 | NPC1 (0.71) | ALOX5LMNAHPGDMAPTNPC1 | |
| SCHEMBL31556116 | 0.87 | MAOB (0.58) | ALOX5LMNAMAPTNPC1MAOB | |
| SCHEMBL3235219 | 0.87 | ALOX5 (0.61) | ALOX5LMNAHPGDMAPTNPC1 | |
| SCHEMBL978502 | 0.86 | RAB9A (0.71) | LMNAHPGDMAPTNPC1MAOB | |
| SCHEMBL7939669 | 0.85 | LMNA (0.53) | LMNAHPGDMAPTNPC1MAOB | |
| SCHEMBL976424 | 0.85 | MAOB (0.73) | LMNAHPGDMAOBMRGPRX4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| EP-1680397-A2 | NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006069153-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005040102-A2 | NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-06 | — | — | WO | disclosed |
| US-5061399-A | FERROELECTRICITY | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1991-10-29 | — | — | US | disclosed |
| EP-0302875-B1 | OPTICALLY ACTIVE NAPHTHALENE COMPOUNDS AND LIQUID CRYSTAL COMPOSITIONS CONTAINING THEM | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN (GB) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | ALOX5 329/4885LMNA 1596/4885HPGD 459/4885 |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | ALOX5 1400/4885LMNA 2939/4885HPGD 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.